# OnCo record olvimulogene-nanivacirepvec (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/olvimulogene-nanivacirepvec/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "olvimulogene-nanivacirepvec" ;
  schema:name "Olvimulogene nanivacirepvec"@en ;
  schema:alternateName "GL-ONC1 and GLV-1h68"@en, "Olvi-Vec"@en, "GL-ONC"@en, "GLV-1h68"@en ;
  schema:description "Olvimulogene nanivacirepvec is an experimental oncolytic virus from Genelux in phase 3 trials for ovarian cancer and non-small-cell lung cancer, with its target not yet stated publicly."@en ;
  schema:url <https://onco.cc/drugs/olvimulogene-nanivacirepvec/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=Olvimulogene%20nanivacirepvec>, <https://www.genelux.com> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "oncolytic virus" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/nsclc/> ;
  onco:companies <https://onco.cc/companies/genelux/> ;
  onco:trials <https://onco.cc/trials/nct05281471/>, <https://onco.cc/trials/nct06463665/> .